Hikma Pharmaceuticals PLC
HIK
Company Profile
Business description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
Contact
10 Portman Square
LondonW1H 6AZ
GBRT: +44 2073992760
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,603
Stocks News & Analysis
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,846.10 | 77.80 | -0.87% |
| CAC 40 | 8,117.78 | 61.99 | -0.76% |
| DAX 40 | 25,440.81 | 127.75 | -0.50% |
| Dow JONES (US) | 52,421.20 | 152.09 | -0.29% |
| FTSE 100 | 10,697.57 | 47.13 | 0.44% |
| HKSE | 24,725.80 | 191.80 | -0.77% |
| NASDAQ | 26,186.41 | 146.62 | -0.56% |
| Nikkei 225 | 63,634.70 | 141.71 | 0.22% |
| NZX 50 Index | 13,484.22 | 76.47 | -0.56% |
| S&P 500 | 7,619.98 | 37.00 | -0.48% |
| S&P/ASX 200 | 8,669.40 | 80.50 | -0.92% |
| SSE Composite Index | 3,870.39 | 14.95 | -0.38% |